ARCTIC: Durvalumab plus tremelimumab and durvalumab monotherapy vs SoC in >= 3L advanced NSCLC treatment
D. M. Kowalski,N. Reinmuth,S. V. Orlov,J. R. Fischer,S. Sugawara, S. Mandziuk, D. M. Medine,S. Novello,Y. Takeda,R. A. Soo, K. Park,M. McCleod,S. L. Geater,M. Powell,R. May,P. Stockman,D. Planchard Annals of Oncology(2018)
AI 理解论文
溯源树
样例